Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer

Marín-Aguilera, M.; Jares, P.; Sanfeliu, E.; Villacampa, G.; Hernández-lllán, E.; Martínez-Puchol, A.I.; Shankar, S.; González-Farré, B.; Waks, A.G.; Brasó-Maristany, F.; Pardo, F.; Manning, D.K.; Abery, J.A.; Curaba, J.; Moon, L.; Gordon, O.; Galván, P.; Wachirakantapong, P.; Castillo, O.; Nee, C.M.; Blasco, P.; Senevirathne, T.H.; Sirenko, V.; Martínez-Sáez, O.; Aguirre, A.; Krop, I.E.; Li, Z.; Spellman, P.; Metzger Filho, O.; Polyak, K.; Michaels, P.; Puig-Butillé, J.A.; Vivancos, A.; Matito, J.; Buckingham, W.; Perou, C.M.; Villagrasa-González, P.; Prat, A.; Parker, J.S.; Paré, L.

doi:10.1016/j.esmoop.2024.102903

ESMO Open

2024

DOI: 10.1016/j.esmoop.2024.102903

|View full text |Cite

Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer

M. Marín-Aguilera,

P. Jares,

E. Sanfeliu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

Martín,

Stecklein,

Gluz

et al. 2024

Annals of Oncology

View full text Add to dashboard Cite

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

Martín,

Stecklein,

Gluz

et al. 2024

Annals of Oncology

View full text Add to dashboard Cite

Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance

Waks,

Martínez-Sáez,

Tarantino

et al. 2024

Nat Rev Clin Oncol

View full text Add to dashboard Cite

Genomic tests for risk stratification in patients with early human epidermal growth factor receptor 2-positive breast cancer

Berton Giachetti,

Giordano,

Taurelli Salimbeni

et al. 2024

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review The purpose of this review is to provide a comprehensive overview of human epidermal growth factor receptor 2 (HER2) genomic tests, particularly focusing on the most recent developments and looking at the future prospects of this field, yet to be thoroughly explored. Recent findings HER2DX is a multifeatured assay, retrospectively proved to add prognostic information and to predict pathological complete response (pCR) in patients with HER2-positive early breast cancer (EBC) undergoing neoadjuvant treatment containing HER2-directed agents. Preliminary data have shown that the assay maintains its predictive capabilities even in the context of chemotherapy-free, anti-HER2 neoadjuvant regimens, potentially selecting patients suitable for treatment de-escalation, having highly HER2-driven malignancies. Summary Multigene prognostic assays have become essential tools in the management of EBC, providing crucial information for risk stratification.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer

Cited by 5 publications

References 14 publications

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance

Genomic tests for risk stratification in patients with early human epidermal growth factor receptor 2-positive breast cancer

Contact Info

Product

Resources

About